Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 12/20 | 0.45 |
| ▸ | CA1 | P00915 | 9/20 | 0.45 |
| ▸ | CA9 | Q16790 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 7/20 | 0.40 |
| ▸ | CA4 | P22748 | 5/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.40 |
| ▸ | CA5A | P35218 | 5/20 | 0.39 |
| ▸ | CA6 | P23280 | 4/20 | 0.39 |
| ▸ | CA7 | P43166 | 4/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1778288 | 0.81 | HTR6 (0.45) | LMNAPOLBKDM4EMAPT | |
| SCHEMBL1771699 | 0.76 | ALDH1A1 (0.45) | LMNAMEN1KMT2ATDP1KDM4E | |
| SCHEMBL20996058 | 0.76 | ATM (0.39) | TDP1KDM4EMAPT | |
| SCHEMBL193716 | 0.72 | LMNA (1.00) | LMNACA2CA1CA9MEN1 | |
| SCHEMBL5792614 | 0.72 | LCK (0.43) | POLBTDP1KDM4EMAPT | |
| SCHEMBL3264399 | 0.72 | MEN1 (0.47) | MEN1KMT2APOLBTDP1MAPT | |
| SCHEMBL2798405 | 0.72 | KDM4E (0.45) | LMNAMEN1KMT2ATDP1KDM4E | |
| SCHEMBL369538 | 0.72 | CYP2A6 (0.45) | MEN1KMT2AKDM4EMAPT | |
| SCHEMBL1826895 | 0.72 | CYP2A6 (0.45) | LMNAMEN1KMT2AGAAMAPT | |
| SCHEMBL607157 | 0.72 | CYP1A2 (0.45) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116462740-A | Design method for optimizing and improving OGT-polypeptide binding affinity | 江南大学 | 2023-07-21 | — | — | CN | disclosed |
| US-20210346367-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-11 | — | — | US | disclosed |
| WO-2020047251-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-03-05 | — | — | WO | disclosed |
| US-20170166558-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166558-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-15 | — | — | US | disclosed |
| WO-2016004180-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016004180-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-01-07 | — | — | WO | disclosed |
| US-8957075-B2 | O-GlcNAc transferase inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-02-17 | — | — | US | disclosed |
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-03 | — | — | US | disclosed |
| EP-2438046-A2 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | President and Fellows of Harvard College (US) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010141074-A3 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2010141074-A2 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166558-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | OGA, OGT, CSGALNACT1 | LMNA 4673/4885CA2 2224/4885CA1 3231/4885 |
| US-20210346367-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | OGT, OGA, UGGT1 | LMNA 3041/4885CA2 1093/4885CA1 650/4885 |
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | OGA, OGT, UGGT1 | LMNA 4381/4885CA2 1422/4885CA1 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.